Canada news from FiercePharma
News
New Canadian rules to delay big generics
Generics makers are up in arms over proposed patent rules in Canada. The drug copycats say the rules will delay generic Lipitor and several other blockbusters by as much as two years. (Can you hear Read more...
Enbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...
Lundbeck poaches CEO from Wyeth ranks
Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president Read more...
BMS swallows Canada's Erbitux price
Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005, Read more...
ALSO NOTED: Boston Scientific announces 2,300 layoffs; Galenica to buy Canada's Aspreva for $915 million;
> Boston Scientific announced worldwide layoffs of 2,300 as part of a restructuring plan that includes selling off some business units and generalized cost-cutting. Read more...
SPOTLIGHT: Canadians prepare OxyContin lawsuit
OxyContin class action lawsuit A Canadian lawyer is putting the finishing touches on a class-action lawsuit that pits patients hooked on the pain drug OxyContin against its maker, Read more...
Get more Canada coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight